Differences in lung and lobe volumes between supine and upright computed tomography in patients with idiopathic lung fibrosis

Chubachi, Shotaro; Okamori, Satoshi; Yamada, Yoshitake; Yamada, Minoru; Yokoyama, Yoichi; Niijima, Yuki; Kamata, Hirofumi; Ishii, Makoto; Fukunaga, Koichi; Jinzaki, Masahiro

doi:10.1038/s41598-022-24157-x

Cited by 4 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Owing to concerns regarding transmission, COVID-19 complicates the assessment of pulmonary function in the acute phase 34. Previous reports showed that CT-derived lung volume strongly correlated with the pulmonary function test results 8 9. Therefore, CT-derived lung volume could serve as a surrogate marker for the physiological assessment of COVID-19 in the acute phase.…”

Section: Discussionmentioning

confidence: 99%

“… 34 Previous reports showed that CT-derived lung volume strongly correlated with the pulmonary function test results. 8 9 Therefore, CT-derived lung volume could serve as a surrogate marker for the physiological assessment of COVID-19 in the acute phase. In this study, patients with decreased lung volume exhibited a higher incidence of multiorgan complications.…”

Section: Discussionmentioning

confidence: 99%

“…Chest CT is extensively used to diagnose COVID-19 and predict its severity 6 7. The measurement of lung volume using chest CT has been reported to be a simple and useful indicator of various lung diseases, including chronic obstructive disease (COPD) and idiopathic pulmonary fibrosis (IPF), where CT-derived lung volume correlates with pulmonary function test results 8–11. Recent studies have indicated its usefulness in assessing disease activity, especially IPF because it enables the evaluation of longitudinal lung volume reduction resulting from lung fibrosis 12 13.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lung volume measurement using chest CT in COVID-19 patients: a cohort study in Japan

Otake,

Shiraishi,

Chubachi

et al. 2024

BMJ Open Resp Res

Self Cite

View full text Add to dashboard Cite

ObjectiveThis study aimed to investigate the utility of CT quantification of lung volume for predicting critical outcomes in COVID-19 patients.MethodsThis retrospective cohort study included 1200 hospitalised patients with COVID-19 from 4 hospitals. Lung fields were extracted using artificial intelligence-based segmentation, and the percentage of the predicted (%pred) total lung volume (TLC (%pred)) was calculated. The incidence of critical outcomes and posthospitalisation complications was compared between patients with low and high CT lung volumes classified based on the median percentage of predicted TLCct(n=600 for each). Prognostic factors for residual lung volume loss were investigated in 208 patients with COVID-19 via a follow-up CT after 3 months.ResultsThe incidence of critical outcomes was higher in the low TLCct(%pred) group than in the high TLCct(%pred) group (14.2% vs 3.3%, p<0.0001). Multivariable analysis of previously reported factors (age, sex, body mass index and comorbidities) demonstrated that CT-derived lung volume was significantly associated with critical outcomes. The low TLCct(%pred) group exhibited a higher incidence of bacterial infection, heart failure, thromboembolism, liver dysfunction and renal dysfunction than the high TLCct(%pred) group. TLCct(%pred) at 3 months was similarly divided into two groups at the median (71.8%). Among patients with follow-up CT scans, lung volumes showed a recovery trend from the time of admission to 3 months but remained lower in critical cases at 3 months.ConclusionLower CT lung volume was associated with critical outcomes, posthospitalisation complications and slower improvement of clinical conditions in COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lung volume measurement using chest CT in COVID-19 patients: a cohort study in Japan

Otake,

Shiraishi,

Chubachi

et al. 2024

BMJ Open Resp Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ROG represents an estimated mean opacity value of parenchymal abnormalities, which was calculated for each patient by summing the values for all lobes and dividing them by five (the total number of lobes). The middle lobe values were given half the weight of the other four lobes ( 14 ). The patients were grouped by opacity extension at 10 months in either the low-ROG group with no or only minor opacities on CT (up to 5%, n = 37) or in the high-ROG group with more widespread opacities (>5%, n = 81) and moderate-to-severe opacities.…”

Section: Methodsmentioning

confidence: 99%

Residual radiological opacities correlate with disease outcomes in ICU-treated COVID-19

Björnson,

Svensson,

et al. 2024

Front. Med.

View full text Add to dashboard Cite

BackgroundFew studies consider both radiological and functional outcomes in COVID-19 survivors treated in the intensive care unit (ICU). We investigated clinical findings and pulmonary abnormalities on chest computed tomography (CT) and compared outcomes of severe versus mild-moderate acute respiratory distress syndrome (ARDS) on long-term follow-up.MethodsThis longitudinal cohort study included 118 COVID-19 patients (median age, 58 years; 79% men). Thoracic CT scans were performed 4, 10, and 22 months after hospital discharge. Two independent blinded radiologists analyzed the 10 months scans and scored the radiology findings semi-quantitatively, as no/minor versus widespread opacities [low-radiology opacity grade (ROG) versus high-ROG]. ARDS severity was based on the PaO2/FiO2 ratio. The 6 min walk test (6MWT) was performed after 3 and 9 months, and lung diffusion capacity for carbon monoxide (DLCO) and lung volume measurement after 9 and 15 months. Dynamic spirometry was done at all time points. Residual symptoms and health-related quality-of-life (HRQL) were evaluated using validated questionnaires.ResultsAt 10 months, most patients (81/118; 69%) were classified as high-ROG, of which 70% had severe ARDS during hospitalisation; 69% of those with mild-moderate ARDS also had high-ROG. Patients with high-ROG had longer ICU stay and lower PaO2/FiO2 during hospitalisation (p < 0.01). At 9 months follow-up, patients with high-ROG had smaller lung volumes as % of predicted values [mean (±CI): 80 (77–84) vs. 93 (88–98) (p < 0.001)], lower DLCO as % of predicted values [74 (70–78) vs. 87 (82–92) (p < 0.001)], lower oxygen saturation during 6MWT (p = 0.02), and a tendency to more severe dyspnoea (p = 0.07), but no difference was found in HRQL compared with no/minor ROG (p = 0.92). A higher opacity score was related to lower DLCO at follow-up (r = −0.48, p < 0.001, Spearman rank test). Severe ARDS patients had slightly more severe fatigue at 9 months compared to mild–moderate, but no differences in dyspnoea or lung function at follow-up. Fibrotic-like changes were found in 93% of patients examined with CT scans at 2 years (55/118; 47%). Severe ARDS could predict widespread opacities (ROG > 25%) in most patients at follow-up at 10 months (AUC 0.74).ConclusionResidual radiological abnormalities in ICU-treated COVID-19 patients, evaluated for up to 2 years, relate to persisting symptoms and impaired lung function, demanding careful follow-up regardless of ARDS severity at hospitalisation.

show abstract

“…These disorders are varied in character with overlapping clinical manifestations, making proper diagnosis and monitoring extremely difficult. In the field of respiratory medicine, high-resolution computed tomography (HRCT) has become a crucial instrument, providing unmatched insights into the complex structural alterations linked to a range of interstitial lung disorders [2]. We also investigated the finer points of HRCT imaging in order to clarify its monitoring and diagnostic use with respect to ILDs.…”

Section: Introductionmentioning

confidence: 99%

High-Resolution Computed Tomography in Diagnosing and Monitoring Various Interstitial Lung Diseases

BHARAT JAIN,

KAPIL VYAS,

SRISHTI

et al. 2024

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Interstitial lung diseases (ILDs) are difficult to diagnose and require accurate imaging methods. The purpose of this work is to investigate ILD patterns and their relationships to pulmonary function using high-resolution computed tomography (HRCT). The aim is to augment our comprehension of ILDs, thereby facilitating customized approaches to diagnosis and treatment Methods: We recruited 50 ILD patients with radiological and clinical issues for a single-center trial. Spirometric data, symptoms, and demographics were recorded on comprehensive patient proformas. An expert radiologist used a Siemens-Somatom 6-slice CT scanner to analyze the HRCT. Pulmonary function indices were obtained using spirometry, which was carried out using a Medisoft Spiro Air spirometer. Results: In fifty cases with ILD, common features on HRCT were uneven pleural borders, ground glass opacities, and septal/subpleural lines. The complex interaction between radiological symptoms and respiratory health was highlighted by the substantial correlations seen between HRCT severities; extent scores, and reduced pulmonary function. Conclusion: The study reinforces the necessity for individualized diagnostic and treatment methods in the ILD respiratory landscape by providing detailed insights into their disease patterns and relationships.

show abstract

Differences in lung and lobe volumes between supine and upright computed tomography in patients with idiopathic lung fibrosis

Cited by 4 publications

References 43 publications

Lung volume measurement using chest CT in COVID-19 patients: a cohort study in Japan

Lung volume measurement using chest CT in COVID-19 patients: a cohort study in Japan

Residual radiological opacities correlate with disease outcomes in ICU-treated COVID-19

High-Resolution Computed Tomography in Diagnosing and Monitoring Various Interstitial Lung Diseases

Contact Info

Product

Resources

About